A comprehensive and systematic review on potential anticancer activities of eugenol: From pre-clinical evidence to molecular mechanisms of action.

Abstract

BACKGROUND:

Eugenol (1-allyl-4-hydroxy-3-methoxybenzene) is an important simple phenolic compound mainly derived from Syzygium aromaticum and many other plants. It is traditionally used in ayurveda and aromatherapy for the healing of many health problems. It also has significant applications in dentistry, agriculture, and flavour industry. This simple phenol has an eclectic range of pharmacological properties, such as antioxidant, anti-inflammatory, and anticancer activities. It is regarded as safe by the Food and Agricultural Organization of the United Nations due to its non-carcinogenic and non-mutagenic properties.

PURPOSE:

The aim of this comprehensive review is to present a critical and systematic assessment of the antitumor ability of eugenol and its associated molecular targets in various cancers.

METHODS:

It was carried out following the preferred reporting items for systematic reviews and meta-analysis guidelines. Risk of bias assessment was performed using the SYstematic review centre for laboratory animal experimentation guidelines. The literature search was performed in standard databases such as Science Direct, PubMed, Google Scholar, Scopus, and Web of Science using the keywords 'eugenol' or 'eugenol essential oil' and 'anti-cancer properties of eugenol'.

RESULTS:

The scientific information from fifty-three studies was encompassed in the present review work. Eugenol exhibits significant anticancer effects in a variety of biological pathways, namely apoptosis, autophagy, cell cycle progression, inflammation, invasion, and metastasis. Eugenol-induced apoptosis has been noticed in osteosarcoma, skin tumors, melanoma, leukemia, gastric and mast cells. It decreases the expression of cyclin D1, cyclin B, proliferating cell nuclear antigen, nuclear factor-ƙB, inhibitor of nuclear factor ƙB, and B-cell lymphoma-2. Eugenol increases the expression of B-cell lymphoma-2 (BCL-2) associated X, BH3-interacting domain death agonist, BCL-2 associated agonist of cell death, apoptotic protease activating factor 1, cytochrome c, p21, and p53.

CONCLUSION:

The anticancer potential exhibited by eugenol is mainly attributed to its anti-metastatic, anti-proliferative, anti-angiogenic, anti-inflammatory, cell cycle arrest, apoptotic, and autophagic effects. Hence, the use of eugenol alone or along with other chemotherapeutic anticancer agents is found to be very effective in cancer therapy.

• Authors: Syeda Nurunnesa Begum, Anindya Sundar Ray, Chowdhury Habibur Rahaman
• Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology (Phytomedicine) Vol. 107 Pg. 154456 (Dec 2022) ISSN: 1618-095X [Electronic] Germany
• PMID: 36152592 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: Copyright © 2022 Elsevier GmbH. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Antineoplastic Agents
• Antioxidants
• Apoptotic Protease-Activating Factor 1
• Cyclin B
• Cyclin D1
• Cytochromes c
• Eugenol
• Oils, Volatile
• Phenols
• Proliferating Cell Nuclear Antigen
• Proto-Oncogene Proteins c-bcl-2
• Tumor Suppressor Protein p53

Topics

• Animals
• Anti-Inflammatory Agents (pharmacology)
• Antineoplastic Agents (pharmacology)
• Antioxidants
• Apoptotic Protease-Activating Factor 1
• Cyclin B
• Cyclin D1
• Cytochromes c
• Eugenol (pharmacology, therapeutic use)
• Neoplasms (drug therapy)
• Oils, Volatile
• Phenols
• Proliferating Cell Nuclear Antigen
• Proto-Oncogene Proteins c-bcl-2
• Tumor Suppressor Protein p53